Cases & Deals

  • Home
  • Practices
  • Celgene licenses to Cambrex certain chiral intermediate chemistries

Share

Celgene licenses to Cambrex certain chiral intermediate chemistries

January 2010

Client(s) Celgene Corporation

Jones Day represented Celgene Corporation in its licensing to Cambrex of patents and technology related to the manufacture of certain chiral intermediate chemistries. The licensing was part of a settlement that concluded litigation initiated by Cambrex against Celgene for a dispute in connection with the sale of Celgene's chiral intermediate business to Cambrex in 1997 and litigation initiated by Celgene against Cambrex for patent infringement.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.